Total cases |
1197 |
325 |
639 |
Age years |
76 (18–102) |
72 (19–102) |
67 (19–99) |
Patient sex |
|
|
|
Female |
708 (59.1%) |
173 (53.2%) |
332 (52%) |
Male |
483 (40.4%) |
152 (46.8%) |
291 (45.5%) |
Unknown |
6 (0.5%) |
|
16 (2.5%) |
Death |
223 (18.6%) |
53 (16.3%) |
82 (12.8%) |
Global time in days to thrombotic event |
3 (0–52) |
2 (0–63) |
5 (0–55) |
Venous thrombotic events |
381 (31.8%) |
80 (24.6%) |
334 (52.3%) |
Age years |
62 (21–98) |
58.5 (19–96) |
63 (18–99) |
Time in days to thrombotic event |
4 (0–50) |
4 (0–39) |
6 (0–55) |
Pulmonary embolism |
211 (17.6%) |
53 (16.3%) |
115 (18%) |
Lower limb thrombosis |
111 (9.3%) |
13 (4%) |
113 (17.7%) |
Cerebral venous sinus thrombosis |
3 (0.3%) |
3 (0.9%) |
6 (0.9%) |
Cerebral venous thrombosis |
1 (0.1%) |
|
1 (0.2%) |
Undetermined venous thrombotic event |
42 (3.5.%) |
10 (3.1%) |
92 (14.4%) |
Others |
13 (1.1%) |
1 (0.3%) |
7 (1.1%) |
Arterial thrombotic events |
813 (67.9%) |
253 (77.6%) |
308 (48.2%) |
Age years |
80 (18–102) |
75 (21–102) |
70 (21–99) |
Time in days to thrombotic event |
2 (0–52) |
2 (0–63) |
2 (0–38) |
Stroke |
561 (46.9%) |
173 (53.1%) |
219 (34.3%) |
Acute myocardial infarction |
238 (19.9%) |
67 (20.6%) |
81 (12.7%) |
Stroke and myocardial infarction |
2 (0.2%) |
3 (0.9%) |
|
Others |
12 (1%)# |
10 (3.1%) |
8 (1.3%)¶ |
Concomitant arterial and venous thrombotic events |
10 (0.8%) |
8 (2.4%) |
4 (0.6%) |
Age years |
70.5 (25–86) |
56 (37–94) |
57.5 (31–71) |
Time in days to thrombotic event |
3.5 (0–11) |
2 (0–22) |
3 (1–12) |
Acute myocardial infarction and pulmonary embolism |
4 (0.3%) |
|
1 (0.15%) |
Stroke and pulmonary embolism |
3 (0.3%) |
6 (1.85%) |
1 (0.15%) |
Stroke and lower limb ischaemia |
1 (0.1%) |
|
|
Arterio-venous fistula thrombosis |
1 (0.1%) |
|
|
Arterial limb ischaemia and lower limb thrombosis |
1 (0.1%) |
|
|
Stroke and lower limb thrombosis |
|
1 (0.31%) |
|
Arterial and venous thrombosis |
|
1 (0.31%) |
|
Pulmonary embolism and multiple thrombosis |
|
|
1 (0.15%) |
Acute myocardial infarction and venous thrombosis |
|
|
1 (0.15%) |
Associated thrombocytopenia and/or immunothrombosis disorders |
32 (2.6%) |
8 (2.4%) |
14 (2.2%) |
Age years |
56 (19–92) |
64 (51–77) |
46.5 (19–73) |
Time in days to event |
4.5 (0–25) |
4 (0–10) |
8 (2–14) |
Thrombocytopenia associated with pulmonary embolism |
2 (0.2%) |
1 (0.3%) |
3 (0.5%) |
Thrombocytopenia associated with acute myocardial infarction |
3 (0.3%) |
|
|
Thrombocytopenia associated with stroke |
13 (1.1%) |
|
1 (0.2%) |
Thrombocytopenia linked to purpura thrombotic thrombocytopenia |
7 (0.6%) |
|
|
DIC |
2 (0.2%) |
|
|
DIC positive lupus anticoagulant associated with visceral venous thrombosis |
1 (0.1%) |
|
|
Positive lupus anticoagulant without thrombosis |
2 (0.2%) |
|
|
Positive lupus anticoagulant associated with pulmonary embolism |
2 (0.2%) |
1 (0.3%) |
|
Positive lupus anticoagulant associated with stroke |
|
4 (1.2%) |
|
Positive lupus anticoagulant associated with myocardial infarction |
|
2 (0.6%) |
|
Thrombocytopenia associated with splenic venous thrombosis |
|
|
1 (0.2%) |
Thrombocytopenia with HIT-like mAb positive and multiple thrombosis |
|
|
1 (0.2%) |
Thrombocytopenia associated with cerebral venous sinus thrombosis |
|
|
4 (0.6%) |
Thrombocytopenia associated with cerebral venous thrombosis |
|
|
1 (0.2%) |
DIC and pulmonary embolism |
|
|
1 (0.2%) |
DIC and stroke |
|
|
2 (0.3%) |